Table I.
Baseline characteristics of the cohort.
| Baseline characteristics | N=373 |
|---|---|
| Median age, (IQR) | 62.2 (55.1-68.9) |
| Sex | |
| Male, n (%) | 282 (75.6%) |
| Female, n (%) | 91 (24.4%) |
| Chronic liver disease etiology | |
| No hepatopathy, n (%) | 10 (2.7%) |
| Hepatitis C, n (%) | 153 (41%) |
| Hepatite B, n (%) | 50 (13.4%) |
| Alcohol, n (%) | 52 (13.9%) |
| NASH/NAFLD, n (%) | 35 (9,4%) |
| Others | 73 (19.6%) |
| Previous treatment* | |
| Transplant, n (%) | 21 (5.6%) |
| Resection, n (%) | 46 (12.3%) |
| Ablation, n (%) | 33 (8.9%) |
| TACE, n (%) | 164 (44%) |
| No previous treatment, n (%) | 173 (46.4%) |
| Child-Pugh class | |
| A, n (%) | 310 (83.1%) |
| B, n (%) | 63 (16.9%) |
| ALBI grade | |
| 1 | 137 (36.7%) |
| 2 | 209 (56.0%) |
| 3 | 27 (7.3%) |
| BCLC stage | |
| B, n (%) | 97 (26%) |
| C, n (%) | 276 (74%) |
| Macrovascular invasion, n (%) | 157 (42.1%) |
| Extrahepatic spread, n (%) | 155 (41.5%) |
| ECOG Performance status, n (%) | |
| 0-1, n (%) | 333 (89,2%) |
| 2, n (%) | 40 (19,8%) |
| Alpha-fetoprotein, median (IQR) | 209 (17-4.291) |
| Ascites, n (%) | 39 (10,5%) |
| Neutrophil-to-lymphocyte ratio, median (IQR) | 2.6 (1.9-4.0) |
| Platelet-to-lymphocyte ratio, median (IQR) | 106.7 (75-169.3) |
IQR, interquartile range; BCLC, Barcelona Clinic Liver Cancer Group; ECOG, Eastern Cooperative Oncology Group.
*Some patients have been treated with more than one previous treatment.